Biosimilars and Biobetters: Interchangeability Issues for Pharmacists, Physicians and Regulators
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Presentation
- By: RAMZAN, Iqbal (The University of Sydney, Australia)
Biologics (and their interchangeable equivalents, biosimilars) and their more efficacious, successors, biobetters) are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, more expensive, and complex in their therapeutic utility. Pharmacists are the primary health professionals who will.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.